Alteration of intracellular structure and function of glyceraldehyde-3-phosphate dehydrogenase: A common phenotype of neurodegenerative disorders?

NeuroToxicology

Volumn 23, Issue 4-5, 2002, Pages 603-609

  Mazzola, Jennifer L ^a,b   Sirover, Michael A ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Glyceraldehyde 3 phosphate dehydrogenase; Neurodegenerative disease; Protein protein interactions; Subcellular localization

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; ANTIPARKINSON AGENT; COMPLEMENTARY DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HUNTINGTIN; RASAGILINE; SELEGILINE;

AGE; ALZHEIMER DISEASE; APOPTOSIS; CELL NUCLEUS; CELL ULTRASTRUCTURE; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENERGY METABOLISM; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; GLYCOLYSIS; HUMAN; HUNTINGTON CHOREA; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTRACELLULAR TRANSPORT; LEWY BODY; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANIMAL; CELL FRACTIONATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; PATHOLOGY; REVIEW; TRINUCLEOTIDE REPEAT;

ANIMALS; APOPTOSIS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; NEURODEGENERATIVE DISEASES; PHENOTYPE; SUBCELLULAR FRACTIONS; TRINUCLEOTIDE REPEATS;

EID: 0036778378     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00062-1     Document Type: Conference Paper

References (61)

1. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. Trends Neurosci 1995;18:11-4.
2. Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altaherr M, Wasmuth J, Buckler A, Church D, Berks M, Micklem G, Durbin R, Dodge A, Read A, Gusella JF, MacDonald ME. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Som Cell Mol Genet 1994;20:27-38.
3. Arahata Y, Hirayama M, Ieda T, Koike Y, Kato T, Tadokoro M, Ikeda M, Ito K, Sobue G. Parieto-occipital glucose hypometabolism in Parkinson's disease with autonomic failure. J Neurol Sci 1999;163:119-26.
4. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999;52:541-6.
5. Burke JR, Enghild JJ, Martin ME, Jou Y-S, Myers RM, Roses AD, Vance JM, Strittmatter WJ. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996;2:347-50.
6. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MMK, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997;41:646-53.
7. Carlile GW, Chalmers-Redman RME, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmcol 2000;57:2-12.
8. Checler F. Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 1995;65:1431-44.
9. Connolly GP, Fibroblast models of neurological disorders: fluorescence measurements studies. Trends Pharmcol Sci 1998;19:171-7.
10. Cooper AJL, Rex K-F, Burke JR, Onodera O, Strittmatter WJ, Roses AD, Blass JP. Transglutaminase-catalyzed inactivation of glyceraldehyde-3-phosphate dehydrogenase and α-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc Natl Acad Sci USA 1997;94:12604-9.
11. Cooper AJL, Sheu K-FR, Burke JR, Strittmatter WJ, Blass JP. Glyceraldehyde-3-phosphate dehydrogenase abnormality in metabolically stressed Huntington's disease fibroblasts. Dev Neurosci 1998;20:462-8.
12. Cupers P, Orlans I, Craessaerts K, Annaert W, De Strooper B. The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J Neurochem 2001;78:68-78.
13. De Rooij KE, Dorsman JC, Smoor MA, Den Dunnen JT, Van Ommen G-JB. Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum Mol Genet 1996;8:1093-9.
14. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel JP, Carraway R, Reeves SA, Boyce FM, Aronin N. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995;14:1075-81.
15. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
16. Gusella JF, MacDonald ME. Trinucleotide instability: a repeating theme in human inherited disorders. Annu Rev Med 1996;47:201-9.
17. Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T, Kalchman M, Hayden MR. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1997;141:1097-105.
18. Hackam AS, Singaraja R, Zhang T, Gan L, Hayden MR. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Hum Mol Genet 1999;8:25-33.
19. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, MacDonald ME. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 2000;9:2789-97.
20. Huynh DP, Scoles DR, Ho TH, Del Bigio MR, Pulst SM. Parkin is associated with actin filaments in neuronal and nonneural cells. Ann Neurol 2000;48:737-44.
21. Ishitani R, Chuang DM. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. Proc Natl Acad Sci USA 1996;93:9937-41.
22. Ishitani R, Kimura M, Sunaga K, Katsube N, Tanaka M, Chuang D-M. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmcol Exp Therap 1996;278:445-7.
23. Ishitani R, Tanaka M, Sunaga K, Katsube N, Chuang D-M. Nuclear localization of over-expressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol Pharmcol 1998;53:701-7.
24. Iwata A, Miura S, Kanazawa I, Sawada M, Nukina N. α-Synuclein forms a complex with transcription factor Elk-1. J Neurochem 2001;77:239-52.
25. Jeffery CJ. Moonlighting proteins. Trends Biochem Sci 1999;24:8-10.
26. Johnston JA, Cowburn RF, Norgren S, Wiehager B, Venizelos N, Winblad B, Vigo-Pelfry C, Schenk D, Lannfelt L, O'Neill C. Increased β-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation. FEBS Lett 1994;354:274-8.
27. Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notchlike manner. J Biol Chem 2001;276:40288-92.
28. Kish SJ, Lopes-Cendes I, Guttman M, Furukawa Y, Pandolfo M, Rouleau GA, Ross BM, Nance M, Schut L, Ang L, DiStefano L. Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Arch Neurol 1998;55:1299-304.
29. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Zoghbi HY, Orr HT. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998;95:41-53.
30. Koshy B, Matilla T, Burright EN, Merry DE, Fischbeck KH, Orr HT, Zoghbi HY. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum Mol Genet 1996;5:1311-8.
31. Kragten E, Lalande I, Zimmerman K, Roggo S, Schindler P, Muller D, van Oostrum J, Waldmeier P, Furst P. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)deprenyl. J Biol Chem 1998;273:5821-8.
32. Kubo S, Ditami T, Noda S, Shimura H, Uchiyama Y, Asakawa S, Minoshima S, Shimizu N, Mizuno Y, Hattori N. Parkin is associated with cellular vesicles. J Neurochem 2001;78:42-54.
33. Laureys S, Salmon E, Garraux G, Peigneux P, Lemaire C, Degueldre C, Franck G. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J Neurol 1999;246:1151-8.
34. Lubec G, Labudova O, Cairns N, Fountoulakis M. Increased glyceraldehyde-3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome. Neurosci Lett 1999;260:141-5.
35. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
36. Maruyama W, Akao Y, Youdim MBH, Davis BA, Naoi M. Transfection-enforced Bcl-2 over-expression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogeneous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 2001;78:727-35.
37. Matsumoto A, Fujiwara Y. Aberrant proteolysis of the β-amyloid precursor protein in familial Alzheimer's disease lymphoblastoid cells. Eur J Biochem 1993;217:21-7.
38. Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner Jr, HN, Robinson RG. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990;28:57-64.
39. Mazzola JL, Sirover MA. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and Huntington's disease fibroblasts. J Neurochem 2001;76:442-9.
40. Mazzola JL, Sirover MA. Alteration of nuclear glyceraldehyde-3-phosphate dehydrogenase structure in Huntington's disease fibroblasts. Mol Brain Res 2002, in press.
41. Nasir J, Goldberg YP, Hayden MR. Huntington disease: new insights into the relationship between CAG expansion and disease. Hum Mol Genet 1996;5:1431-5.
42. Racchi M, Johnston JA, Flood FM, Cowburn RF, Govoni S. Amyloid precursor protein metabolism in fibroblasts with one, two or three copies of the amyloid precursor protein (APP) gene. Biochem J 1999;338:777-82.
43. Saunders PA, Chalecka-Franaszek E, Chuang D-M. Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J Neurochem 1997;69:1820-8.
44. Saunders PA, Chen R-W, Chuang D-M. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. J Neurochem 1999;72:925-32.
45. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci USA 1997;94:11669-74.
46. Selkoe DJ. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994;10:373-403.
47. Shulze H, Schuyler A, Stuber D, Dobeli H, Langen H, Huber G. Rat brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimer's β-amyloid precursor protein. J Neurochem 1993;60:1915-22.
48. Sirover MA. Role of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in normal cell function and in cell pathology. J Cell Biochem 1997;66:133-40.
49. Sirover MA. New insight into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1999;1432:159-84.
50. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goerdert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.
51. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goerdert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73.
52. Sunaga K, Takahashi H, Chuang D-M, Ishitani R. Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Neurosci Lett 1995;200:133-6.
53. Tabrizi SJ, Cleeter MWJ, Xuereb J, Taanman J-W, Cooper JM, Schapira AHV. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999;45:25-32.
54. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000;166:29-43.
55. Tisdale EJ. Glyceraldehyde-3-phosphate dehydrogenase is required for vesicular transport in the early secretory pathway. J Biol Chem 2001;276:2480-6.
56. L/λ and plays a role in microtubule dynamics in the early secretory pathway required for vesicular transport. J Biol Chem 2002;277:3334-41.
57. Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutx Y, Weber C, Agid Y, Hirsch EC, Mandel JL. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 1995;19:104-10.
58. Vaughn JR, Davis MB, Wood NW. Genetics of Parkinsonism: a review. Ann Hum Genet 2001;65:111-26.
59. Vestling M, Cedazo-Minguez A, Adem A, Wiehager B, Racchi M, Lannfelt L, Cowburn RF. Protein kinase C and amyloid precursor protein processing in skin fibroblasts from sporadic and familial Alzheimer's disease cases. Biochim Biophys Acta 1999;1453:341-50.
60. Wood JD, Nucifora Jr, FC, Duan K, Zhang C, Wang J, Kim Y, Schilling G, Sacch N, Liu JM, Ross CA. Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription. J Cell Biol 2000;150:939-48.
61. Yazawa I, Nukina N, Hashida H, Goto J, Yamada M, Kanazawa I. Abnormal gene product identified in hereditary dentatorubal-pallidoluysian (DRPLA) brain. Nat Genet 1995;10:99-103.